CA125 is not useful in prediction of endometrial adenocarcinoma among post menopausal bleeding
DOI:
https://doi.org/10.59325/sjhas.v1i1.31Keywords:
Postmenopausalbleeding, endometrial adenocarcinoma, CA125, curettageAbstract
Postmenopausal bleeding (PMB) is vaginal bleeding that happens at least 12 months after your periods have stopped. This study was conducted in Ibb governorate during 2 years to determine the value of serum CA 125 in predicting endometrial adenocarcinoma among postmenopausal bleeding women. The study included 40 PMB women with age range (45-80 years) and mean of 59.9±8.9 years. Diagnosis of the endometrial curettage revealed 8(20.0%) endometrial adenocarcinoma and 19(80.0%) benign endometrial lesions. The mean CA125 was 26.8±19.7 U/mL, it did not show significant difference between PMB due to endometrial adenocarcinoma or other benign endometrial lesions. This study concluded that measuring serum CA125 is not useful in predicting endometrial adenocarcinoma among post menopausal bleeding women and recommended gynecologist to rely only on histopathological diagnosis among PMB women.
Downloads
Published
How to Cite
Issue
Section
License
copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work.